Cagrilintide
Cagrilintide is a long-acting synthetic analog of amylin, a hormone co-secreted with insulin by the pancreas. It acts as a dual amylin and calcitonin receptor agonist (DACRA), designed to regulate appetite and improve metabolic health.
$ 75.00 USD
Research Overview
Key Benefits
- Appetite Suppression & Satiety
- Slows gastric emptying and promotes a feeling of fullness.
- Helps reduce caloric intake and cravings.
- Weight Loss
- Demonstrated meaningful body weight reductions in clinical trials.
- Especially effective when combined with GLP-1 agonists like semaglutide (the “CagriSema” combo).
- Improved Blood Sugar Control
- Supports better post-meal glucose regulation.
- May benefit individuals with obesity or type 2 diabetes.
- Enhanced Combination Therapy (CagriSema)
- In studies, Cagrilintide + Semaglutide achieved ~20% body weight loss over 68 weeks—more than either agent alone.
- Shows strong potential for long-term obesity and diabetes management.
Why It’s Unique
- Longer half-life than natural amylin, enabling once-weekly dosing.
- Works synergistically with GLP-1 receptor agonists, targeting appetite, metabolism, and glucose regulation through complementary pathways.
Accepting
